Guidelines & Consensus
ctDNA-Based ESR1 Mutation Monitoring in First-Line ER+/HER2- Advanced Breast Cancer
Abdou et alThe oncologist

Circulating tumor DNA (ctDNA) is an emerging modality in precision oncology that facilitates noninvasive genomic profiling, minimal residual disease detection, and dynamic treatment response monitoring. In estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+, HER2-) advanced breast cancer, serial ctDNA assessment allows for the early identification of acquired therapeutic resistance mechanisms, notably emergent estrogen receptor alpha mutations (ESR1m) arising during first-line endocrine-based therapy, as explored in the phase III PADA-1 and SERENA-6 clinical trials.
Despite its potential to guide timely biomarker-directed therapeutic adjustments, routine ctDNA-based ESR1m surveillance has not yet achieved widespread clinical adoption. Translating this approach into standard oncology care necessitates overcoming diagnostic barriers and establishing standardized institutional and patient-scheduling pathways. In response, multidisciplinary experts spanning United States academic and community practice settings convened to address practical feasibility challenges, logistical barriers, and institutional requirements, formulating an opinion-based consensus workflow to guide clinicians in integrating serial ctDNA ESR1m testing into first-line advanced breast cancer management.
Key Takeaways
- A multidisciplinary consensus panel established a flexible clinical workflow framework addressing institutional operations and patient scheduling to facilitate routine ctDNA-based ESR1 mutation monitoring during first-line endocrine therapy for ER+, HER2- advanced breast cancer.
Read the original sourceThe oncologist
